Authors

• Robert A Bermel (ORCID: https://orcid.org/0000-0003-2334-6883)
• Carlos Nos (ORCID: https://orcid.org/0000-0002-3830-4910)
• William M. Carroll (ORCID: https://orcid.org/0000-0002-5088-548X)
• Susanne Clinch (ORCID: https://orcid.org/0000-0002-3458-0117)
• Mark S. Freedman (ORCID: https://orcid.org/0000-0003-1255-9701)
• Ralph H. B. Benedict (ORCID: https://orcid.org/0000-0002-2080-3631)
• Timothy Vollmer (ORCID: https://orcid.org/0000-0002-1539-9830)
• Karen Kadner
• Jens Wuerfel (ORCID: https://orcid.org/0000-0002-0034-8053)
• Ludo Vanopdenbosch
• Thomas Berger (ORCID: https://orcid.org/0000-0001-5626-1144)
• Hans‐Peter Hartung (ORCID: https://orcid.org/0000-0002-0614-6989)
• Catarina Raposo (ORCID: https://orcid.org/0000-0002-1466-1542)
• Inessa Kulyk
• Trygve Holmøy (ORCID: https://orcid.org/0000-0002-2529-5664)
• Francesco Patti (ORCID: https://orcid.org/0000-0002-6923-0846)
• Rana Karabudak (ORCID: https://orcid.org/0000-0003-4272-1482)
• Bruno Brochet (ORCID: https://orcid.org/0000-0003-3824-2796)
• Thomas Kuenzel (ORCID: https://orcid.org/0000-0003-0993-8524)
• Joep Killestein (ORCID: https://orcid.org/0000-0002-6347-5957)
• Gian‐Andrea Thanei
• Amy Perrin Ross

Institutions

• Université de Bordeaux (FR)
• Inserm (FR)
• Düsseldorf University Hospital (DE)
• Heinrich Heine University Düsseldorf (DE)
• Palacký University Olomouc (CZ)

Publication Details

Journal

Neurology

Published

2024-12-03

DOI

https://doi.org/10.1212/wnl.0000000000210049

Citations

9

Primary Topic

Multiple Sclerosis Research Studies

Type

article

Field-Weighted Citation Impact

3.82

Funders

• Bristol-Myers Squibb
• AstraZeneca
• Sanofi
• Biogen
• Teva Pharmaceutical Industries
• Alexion Pharmaceuticals
• Celgene
• F. Hoffmann-La Roche
• Fondazione Italiana Sclerosi Multipla
• TG Therapeutics
• Multiple Sclerosis Society
• Santen
• Università di Catania
• National Institutes of Health
• Genentech
• EMD Serono
• Greenwich Biosciences